THE COTTLE GROUP


PUBLICATIONS

Journal Publications

  1. Gibson J., Cottle R. N. (2026). Gene Therapy: The Current Trajectory of Clinical and Commercial Translation. Biotechnology Progress (under review).
  2. Arthur B., Gibson J., Mehlem R., Haque A., Cottle R. N. (2026). Cas9 Immunogenicity and Challenges for Clinical Translation of CRISPR-Cas9 Mediated Gene Therapy Interventions. Molecular Therapy Nucleic Acids (under review).
  3. Gibson JR, Dhungana A, Pokhrel M, Arthur BB, Adebayo O, Hossack D, Cottle RN. Toward Next-Gen Cell Therapy for Pediatric Patients: Neonatal Hepatocytes Tolerate Electroporation-Mediated Gene Editing and Engraft in the Liver. CRISPR J. 2026 Apr;9(2):103-114. doi: 10.1177/25731599261430830. Epub 2026 Apr 2. PMID: 41928587.
  4. Clark C., Pokhrel M., Arthur B., Suresh P., Ates I., Gibson J., Dhungana A., Mehlem R., Boysia A., Padalkar M. V., Pokhrel A., Echesabal-Chen J., Vonada A., Stamatikos A., Savinova O. V., Grompe M., Cottle R. N. One Shock, Not One Cure: Electroporation Reveals Disease-Specific Constraints in Hepatocyte Gene Editing Therapy. Biology. 2025, 14(8), 1091. doi: 10.3390/biology14081091
  5. Gibson J., Dhungana A., Pokhrel M., Arthur B., Suresh P., Adebayo O., Cottle R. N. Validation of Clinical-Grade Electroporation Systems for CRISPR-Cas9-Mediated Gene Therapy in Primary Hepatocytes for the Correction of Inherited Metabolic Liver Disease. Cells. 2025 May 14;14(10):711. doi: 10.3390/cells14100711. PMID: 40422214; PMCID: PMC12109753.
  6. Ates I., Rathbone T., Stuart C., Barzi M., He G., Major A.M., Srinivasan S., Farris A.B., Bissig K.-D., Cottle R. N. Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1. Hepatology Communications. 2024, 8(5):e0424. doi: 10.1097/HC9.0000000000000424. PMID: 38668730.
  7. Rathbone T., Ates I., Stuart C., Parker T., Cottle R. N. Electroporation-mediated Delivery of Cas9 Ribonucleoproteins and mRNA into Freshly Isolated Primary Mouse Hepatocytes. J. Vis. Exp. 2022 (184), e63828, doi:10.3791/63828
  8. Rathbone T, Ates I, Fernando L, Addlestone E, Lee C, Richards V, Cottle RN. Electroporation-mediated delivery of Cas9 ribonucleoproteins results in high levels of gene editing in primary hepatocytes. The CRISPR Journal. 2022, online.
  9. Salminen A, Allahyari Z, Gholizadeh S, McCloskey MC, Ajalik R, Cottle RN, Gaborski T, and McGrath JL. In vitro studies of transendothelial migration for biological and drug discovery. Frontiers in Medical Technology. 2020. 2:11.
  10. Ates I, Rathbone T, Stuart C, Bridges PH, Cottle RN. Delivery approaches for therapeutic genome editing and challenges. Genes. 2020. 11:E1113.
  11. Bryson TE, Anglin CM, Bridges PH, Cottle RN. Nuclease-mediated gene therapies for inherited metabolic diseases of the liver. Yale J Biol Med. 2017. 90:553-66.

  12. Cottle RN, Lee CM, Bao G. Treating hemoglobinopathies using gene-correction approaches: promises and challenges. Hum Genet. 2016. 135:993-100.
  13. Cottle RN, Lee CM, Archer D, Bao G. Controlled delivery of β-globin-targeting TALENs and CRISPR/Cas9 into mammalian cells for genome editing using microinjection. Sci Rep. 2015; 5:16031.

Other Publications

  1. Cottle R. Electroporation-based delivery for gene editing. Cell & Gene Therapy. 2026 Mar;2(1): 22-26. Epub 2026 Mar 25.
  2. Ates I., Rathbone T., Stuart C., Barzi M., He G., Major A.M., Srinivasan S., Farris A.B., Bissig K.-D., Cottle, R.N. (2023) Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1. bioRxiv, 2023.2009.2004.555940.

Conference Proceedings

  1. Pokhrel M., Dhungana A., Gibson J., Arthur B., Mehlem R., Hossack D., Cortes V., Mango F., Estel S., Pokhrel A., Vonada A., Haque A., Stamatikos A., Savinova O., Grompe M., Cottle R.N. “Electroporation-mediated multiplex gene editing combined with in vivo selection: tailored cell-based gene therapy for familial hypercholesterolemia,” Proceedings of the ASGCT 2026 Annual Meeting, Boston, MA (May 2026). Poster presentation.
  2. Hossack D., Stuart C., Suresh P., Pokhrel M., Dhungana A., Gibson J., Arthur B., Padalkar M., Savinova O., Lee C., Peng C., Bissig-Choisat B., Bissig K. D., Cottle R.N. “Evaluating Chromosomal Translocations in Multiplex CRISPR Editing under Selective Expansion,” Proceedings of the ASGCT 2026 Annual Meeting, Boston, MA (May 2026). Poster presentation.
  3. Adebayo O., Gibson J., Arthur B., Hossack D., Popoola D., Josephs E., Li Y., Cottle R.N. “Comparative evaluation of in vivo and ex vivo LNP-enabled gene editing cell therapy for hereditary tyrosinemia type 1,” Proceedings of the ASGCT 2026 Annual Meeting, Boston, MA (May 2026). Poster presentation.
  4. Gibson G., Arthur B., Roberts J. P., Cottle R.N. “The Techno-economic Viability of Next-Generation Hepatocyte Transplantation Strategies: A Probabilistic Time-to-Event Analysis of Engineered Cell Therapy Modalities as Bridges-to-Definitive-Cure for Liver Disease,” Proceedings of the ASGCT 2026 Annual Meeting, Boston, MA (May 2026). Oral presentation.
  5. Dhungana A., Pokhrel M., Gibson J., Hossack D., Adebayo O., Arthur B., Khan A., Cottle R.N. “Electroporation-assisted cryopreservation of gene-edited primary hepatocytes for scalable off-the-shelf transplantation,” Proceedings of the 2026 Summer Symposium, Clemson University Institute for Human Genetics, Greenwood, SC (May 2026). Poster presentation.
  6. Arthur B., Gibson J., Mehlem R., Dhungana A., Hossack D., Pokhrel M., Adebayo O., Wynton V., Haque A., Cottle R.N. “Cas9 Immunogenicity and Its Impact on Therapeutic Efficacy of CRISPR-Cas9-mediated AAV gene therapy for treating Hereditary Tyrosinemia,” Proceedings of the 2026 Summer Symposium, Clemson University Institute for Human Genetics, Greenwood, SC (May 2026). Poster presentation.
  7. Pokhrel M., Dhungana A., Gibson J., Arthur B., Adebayo O., Hossack D., Cortes V., Khan A., Savinova O., Stamatikos A., Vonada A., Grompe M., Cottle R.N. “Electroporation-mediated multiplex gene editing and selection a promising cell therapy for severe familial hypercholesterolemia,” Proceedings of the 2026 Summer Symposium, Clemson University Institute for Human Genetics, Greenwood, SC (May 2026). Poster presentation.
  8. Adebayo O., Gibson J., Arthur B., Hossack D., Popoola D., Josephs E., Li Y., Cottle R.N. “Comparative evaluation of in vivo and ex vivo LNP-enabled gene editing cell therapy for hereditary tyrosinemia type 1,” Proceedings of the 2026 Summer Symposium, Clemson University Institute for Human Genetics, Greenwood, SC (May 2026). Poster presentation.
  9. Pokhrel M., Dhungana A., Gibson J., Arthur B., Mehlem R., Hossack D., Cortes V. A., Mango F., Estel S., Pokhrel A., Vonada A., Haque A., Stamatikos A., Savinova O.V., Grompe M., Cottle R.N. “Advancing cell-based therapy for familial hypercholesterolemia through electroporation-mediated multiplex gene editing and in vivo selection,” Proceedings of the 7th Annual Research Symposium and Retreat, Digestive Disease Research Center, Medical University of South Carolina, Charleston, SC (April 2026). Oral and poster presentation.
  10. Mehlem R., Vaughn W., Estel S., Mango F., Radomski C., Broderick L., Pokhrel M., Hossack D., Gibson J., Dhungana A., Arthur B., Cottle R.N. “Novel CRISPR Gene Editing Therapy for Inherited Metabolic Liver Disease,” Proceedings of the 21st Annual Focus on Creative Inquiry Forum, Clemson University, Clemson, SC (April 2026). Poster presentation.
  11. Pokhrel M., Dhungana A., Adebayo O., Gibson J., Arthur B., Mehlem R., Hossack D., Cortes-Flores V., Mango F., Estel S., Popoola D., Pokhrel A., Vonada A., Haque A., Joesphs E., Stamatikos A., Savinova O., Li Y., Grompe M., Cottle R.N. “Nonviral-mediated multiplex gene editing combined with in vivo selection: tailored cell-based gene therapy for familial hypercholesterolemia,” Proceedings of the 2026 South Carolina Clinical & Translational Research Scientific Retreat, Charleston, SC (March 2026). Poster presentation.
  12. Cortes-Flores V., Hossack D., Khan A., Gibson J., Clark C., Savinova O.V., Cottle R.N. “Hepatic LDL Uptake Dynamics in Ldlr−/− Mice Following Transplantation of Cas9 Gene-Edited Hepatocytes,” Proceedings of the SC INBRE 17th Annual Science Symposium, Columbia, SC (February 2026). Oral and poster presentation. First Place Poster Prize in Bioengineering category.
  13. Arthur B., Gibson J., Mehlem R., Dhungana A., Hossack D., Pokhrel M., Adebayo O., Wynton V., Haque A., Cottle R.N. “Cas9 Immunogenicity and Its Impact on Therapeutic Efficacy of CRISPR-Cas9-mediated AAV gene therapy for treating Hereditary Tyrosinemia,” Proceedings of the SC INBRE 17th Annual Science Symposium, Columbia, SC (February 2026). Oral and poster presentation.
  14. Adebayo O., Gibson J., Hossack D., Popoola D., Josephs E., Li Y., Cottle R.N. “LNP-mediated gene editing and cell therapy for hereditary tyrosinemia type 1,” Proceedings of the SC INBRE 17th Annual Science Symposium, Columbia, SC (February 2026). Poster presentation.
  15. Gibson J., Dhungana A., Pokhrel M., Arthur B., Adebayo O., Hossack D., Cottle R.N. “An Evaluation of Engraftment Kinetics in Gene-Edited Neonatal Hepatocytes,” Proceedings of the SC INBRE 17th Annual Science Symposium, Columbia, SC (February 2026). Poster presentation.
  16. Stuart C., Hossack D., Minch S., Reeves M., Suresh P., Pokhrel M., Dhungana A., Gibson G., Arthur B., Padalkar M., Eshesabal-Chen J., Savinova O., Stamatikos A., Cottle R.N. “Comparative Analysis of Dual Cas9 and Hybrid Cas9/Cas12a Multiplex Editing Targeting ANGPTL3 and CYPOR with APAP Selection,” Proceedings of the SC INBRE 17th Annual Science Symposium, Columbia, SC (February 2026). Poster presentation.
  17. Pokhrel M., Dhungana A., Gibson G., Arthur B., Adebayo O., Hossack D., Cortes-Flores V., Mango F., Estel S., Savinova O., Stamatikos A., Vonada A., Grompe M., Cottle R.N. “Electroporation-Mediated Multiplex Gene Editing and Selection: Disease-Tailored Gene Therapy for Familial Hypercholesterolemia,” Proceedings of the SC INBRE 17th Annual Science Symposium, Columbia, SC (February 2026). Poster presentation.
  18. Clark C., Pokhrel M., Arthur B., Suresh P., Ates I., Gibson J., Dhungana A., Mehlem R., Boysia A., Padalkar M. V., Pokhrel A., Echesabal-Chen J., Vonada A., Stamatikos A., Savinova O. V., Grompe M., Cottle R.N. “Electroporation in hepatocytes to evaluate a cell-based gene editing strategy for treating homozygous familial hypercholesterolemia,” Proceedings of the AASLD The Liver Meeting 2025, Washington, D. C. (November 2025). Poster presentation
  19. Khan A, Mehlem R, Boysia D, Estel S, Oswald H, Radomski C, Cottle R. “Cell-Based Genome Editing for the Treatment of Familial Hypercholesterolemia,” Proceedings of the 20TH Annual Focus on Creative Inquiry Forum, Clemson University, Clemson, SC (April 2025). Poster presentation.
  20. Gibson J, Dhungana A, Pokhrel M, Arthur B, Suresh P, Adebayo O, Cottle R. “Comparison of electroporation systems for CRISPR-Cas9 mediated gene-editing in primary hepatocytes for the correction of hereditary tyrosinemia type 1,” Proceedings of the SC INBRE 16th Annual Science Symposium, Columbia, SC (February 2025). Poster presentation.
  21. Suresh P, Stuart C, Ates I, Dhungana A, Arthur B, Padalkar M, Savinova O, Echesabal-Chen J, Stamatikos A, Cottle R. “Gene editing combined with APAP diet-mediated selection in LDLR-/- mouse model of familial hypercholesterolemia,” Proceedings of the SC INBRE 16th Annual Science Symposium, Columbia, SC (February 2025). Poster presentation.
  22. Adebayo O, Popoola D, Li Y, Cottle R. “Ex vivo lipid nanoparticle-mediated delivery of CRISPR-Cas9 mRNA into hepatocytes for treatment of familial hypercholesterolemia,” Proceedings of the SC INBRE 16th Annual Science Symposium, Columbia, SC (February 2025). Poster presentation.
  23. Stuart C, Suresh P, Ates I, Pokhrel M, Minich S, Padalkar M, Pokhrel A, Echesabal-Chen J, Vonada A, Grompe M, Stamatikos A, Savinova O, Cottle R. “Ex vivo multiplex knockdown of ANGPTL3 and CYPOR in hepatocytes as a novel cell therapy for familial hypercholesterolemia,” Proceedings of the SC INBRE 16th Annual Science Symposium, Columbia, SC (February 2025). Poster presentation.
  24. Stuart C, Suresh P, Aytes I, Minich S, Adebayo O, Mehlem R, Padalkar M, Savinova O, Echesabal-Chen J, Stamatikos A, Cottle R. "Ex vivo knockdown of ANGPTL3 and CYPOR in hepatocytes: a novel therapy for familial hypercholesterolemia," Biomarkers of Aging Consortium 2024 Biomarkers of Aging Conference, Boston, MA (November 2024). Poster Presentation.
  25. Stuart C, Suresh P, Ates I, Minich S, Adebayo O, Mehlem R, Padalkar M, Savinova O, Echesabal-Chen J, Stamatikos A, Cottle R. "Ex vivo knockdown of ANGPTL3 and CYPOR in hepatocytes: a novel therapy for familial hypercholesterolemia," Oral and poster presentation abstracts, Southeastern Medical Scientists Symposium 2024, Nashville, TN (September 2024). Poster Presentation.
  26. Adebayo O, Popoola D, Li Y, Cottle R. “Ex vivo lipid nanoparticle-mediated delivery of CRISPR-Cas9 mRNA into hepatocytes for treatment of familial hypercholesterolemia,” Abstracts of papers presented at the CSHL 2024 Meeting on Genome Engineering CRISPR Frontiers, Cold Spring Harbor, NY (August 2024).
  27. Stuart C, Ates I, Suresh P, Minich S, Padalkar M, Savinova O, Echesabal-Chen J, Stamatikos A, Grompe M, Cottle R. “Multiplex knockdown of Angtpl3 and Cypor as a novel treatment for familial hypercholesterolemia,” Abstracts of papers presented at the CSHL 2024 Meeting on Genome Engineering CRISPR Frontiers, Cold Spring Harbor, NY (August 2024).
  28. Adebayo O, Popoola D, Li Y, Cottle R. “Ex vivo lipid nanoparticle-mediated delivery of CRISPR-Cas9 mRNA into hepatocytes to treat familial hypercholesterolemia,” Proceedings of the Center of Biomedical Research Excellence in Human Genetics 2024 Summer Symposium Gene Regulatory Mechanisms in Health and Disease, Greenwood, SC (May 2024). Podium presentation.
  29. Stuart C, Suresh P, Ates I, Minich S, Adebayo O, Mehlem R, Padalkar M, Savinova O, Echesabal-Chen J, Stamatikos A, Cottle R. “Ex vivo knockdown of ANGPTL3 and CYPOR in hepatocytes: a novel therapy for familial hypercholesterolemia,” Proceedings of the Center of Biomedical Research Excellence in Human Genetics 2024 Summer Symposium Gene Regulatory Mechanisms in Health and Disease, Greenwood, SC (May 2024).
  30. Suresh P, Stuart C, Ates I, Minich S, Padalkar M, Savinova O, Eshesabal-Chen J, Stamatikos A, Cottle R N. “Gene editing combined with APAP diet in Ldlr-/- mouse model of familial hypercholesterolemia,” Proceedings of the SC INBRE 15th Annual Science Symposium, Columbia, SC (February 2024).
  31. Adebayo O, Popoola D, Li Y, Cottle R N. “Ex vivo lipid nanoparticle-mediated delivery of Cypor-CRISPR-Cas9 into Hepatocytes for Familial Hypercholesterolemia therapy,” Proceedings of the SC INBRE 15th Annual Science Symposium, Columbia, SC (February 2024). Poster and Podium.
  32. Stuart C, Ates I, Minich S, Padalkar M, Savinova O, Eshesabal-Chen J, Stamatikos A, Cottle R N. “Ex vivo multiplex knockdown of ANGPTL3 and CYPOR in hepatocytes as a novel cell therapy for familial hypercholesterolemia,” Proceedings of the SC INBRE 15th Annual Science Symposium, Columbia, SC (February 2024
  33. Ates I, Rathbone T, Stuart C, Major A, Barzi M, Srinivasan S, Bissig KD, Cottle R N. “Engraftment of hepatocytes gene edited ex vivo for the treatment of inherited metabolic liver disease,” Proceedings of the ASGCT 26st Annual Meeting, Los Angeles, CA (May 2023).
  34. Ates I, Stuart C, Minich S, Mugdha P, Savinova S, Eshesabal-Chen J, Stamatikos A, Cottle R N. “Multiplex knockdown of ANGPTL3 and CYPOR as a novel treatment for familial hypercholesterolemia,” Proceedings of the ASGCT 26st Annual Meeting, Los Angeles, CA (May 2023).
  35. Ates I, Rathbone T, He G, Barzi M, Bissig KD, Cottle R. “Electroporation-mediated delivery of Cas9 ribonucleoproteins and mRNA corrects hereditary tyrosinemia type I in a mouse model,” Proceedings of the 2022 Meeting on Genome Engineering: Frontiers of CRISPR/Cas9. CSHL, (August 2022).
  36. Reeves M, Stuart C, Padalkar M, Savinova O, Echesabal-Chen J, Stamatikos A, Cottle R. “Optimizing CRISPR/Cas9-mediated knockdown of ANGPTL3 in liver cell lines and primary mouse hepatocytes,” Proceedings of the 2022 Meeting on Genome Engineering: Frontiers of CRISPR/Cas9. CSHL, (August 2022).
  37. Minich S, Chen A, Cottle R. “Genomic editing using prime editors,” Proceedings of the of the Focus on Creative Inquiry Poster Forum, Clemson University, Clemson, SC (April 2022).
  38. Yates C, O’Neill Elizabeth, Dempster T, Cottle R. “Disposable point-of-care home testing platform for metabolic diseases,” Proceedings of the of the Focus on Creative Inquiry Poster Forum, Clemson University, Clemson, SC (April 2022). 3rd Place for the FoCI Printed Poster Award.
  39. Arnold CJ, Suresh P, Cottle R. “Lipid nanoparticle-mediated delivery of CRISPR-Cas9 into hepatocytes,” Proceedings of the of the Focus on Creative Inquiry Poster Forum, Clemson University, Clemson, SC (April 2022).
  40. Ates I, Rathbone R, Stuart C., Cottle R. Electroporation-mediated delivery of CRISPR-Cas9 into hepatocytes for treatment of inherited metabolic liver disease,” Proceedings of the AASLD The Liver Meeting. Virtual meeting (November 2021).
  41. Ates I, Rathbone T, Cottle R. Engraftment of hepatocytes gene-edited ex vivo for the treatment of inherited metabolic liver disease,” Proceedings of the 2021 Meeting on Genome Engineering: Frontiers of CRISPR/Cas9. CSHL, Virtual Meeting (August 2021).
  42. Rathbone T, Ates I, Cottle R. Nonviral delivery of CRISPR-Cas9 into primary hepatocytes ex vivo as a therapeutic strategy for inherited metabolic disease,” Proceedings of the 2021 Meeting on Genome Engineering: Frontiers of CRISPR/Cas9. CSHL, Virtual Meeting (August 2021).
  43. O'Neill E, Khodab A, Bisaccio P, OSullivan T, Shropshire K, Cottle R.Disposable Point-of-Care Home Testing Platform for Metabolic Disease. Proceedings of the Focus on Creative Inquiry Poster Forum, Clemson University, Clemson, SC (April 2021).
  44. Betsill W, Chen A, Cottle R. Genomic Editing and Mutation Repair Using Prime Editors. Proceedings of the Focus on Creative Inquiry Poster Forum, Clemson University, Clemson, SC (April 2021).
  45. Rathbone T, Ates I, Stuart C, Cottle R. , Comparison of non-viral delivery of cas9 reagents into hepatocytes for therapeutic gene editing. Proceedings of the 2021 SC INBRE Science Symposium, Virtual Meeting (January 2021).
  46. Ates I, Rathbone T, Cottle R. Engraftment of hepatocytes gene edited ex vivo for the treatment of inherited metabolic liver disease. Proceedings of the 2021 SC INBRE Science Symposium, Virtual Meeting (January 2021).
  47. Betsill W, Rathbone T, Lynn S, Cottle R. The effects of buffer composition on the viability and efficiency of electroporation on Huh7 cells. Proceedings of the 2021 SC INBRE Science Symposium, Virtual Meeting (January 2021).
  48. Rathbone T, Ates I, Fernando L, Cottle R. Non-viral delivery of CRISPR-Cas9 for therapeutic gene editing in hepatocytes. Proceedings of the 2019 Meeting on Genome Engineering: Frontiers of CRISPR/Cas9. CSHL, Cold Spring Harbor, NY (October 2019).
  49. Rathbone T, Ates I, Fernando L, Cottle R. Optimization of non-viral methods for delivery of CRISPR-Cas9 and donor templates to treat hereditary tyrosinemia. Proceedings of the 2019 BMES Annual Meeting. BMES, Philadelphia, PA (October 2019).
  50. Nadolski G, Salvadore K, Addlestone E, Fernando L, Cottle RN. Optimization of gene editing tools for precise gene editing. Proceedings of the Focus on Creative Inquiry Poster Forum, Clemson University, Clemson, SC (April 2019).
  51. Cottle R, The promise of cell-based gene therapies using non-viral delivery approaches. Proceeding of the 2nd Annual Summit on Stem Cell Research, Cell & Gene Therapy, Atlanta, GA (November 2018).
  52. Rathbone T, Fernando L, Cottle R. Optimization of non-viral methods for delivery of CRISPR-Cas9 and donor templates to treat familial hypercholesterolemia. Proceedings of the 2018 Annual Meeting. BMES, Atlanta, GA (October 2018).
  53. Bryson T, Rathbone T, Cottle R. Comparison of CRISPR-Cas9 and Cas12a on-target activity in Hepa 1-6 cells. Proceedings of the 2018 Annual Meeting. BMES, Atlanta, GA (October 2018).
  54. Rathbone T, Bryson TE, Bridges PH, Cottle RN. Non-viral mediated delivery of CRISPR-Cas9 and donor templates in hepatocytes to treat inherited metabolic diseases of the liver. Proceedings of the SC INBRE Science Symposium. SC INBRE, Columbia, SC (August 2018). Winner of poster competition for Engineering category.
  55. Cottle R, Novel gene therapy strategy using CRISPR-Cas nucleases and donor template for metabolic liver disease. Proceedings of SC INBRE Science Symposium, Columbia, SC (August 2018).
  56. Rathbone T, Bryson TE, Bridges PH, Cottle RN. Non-viral mediated delivery of CRISPR-Cas9 and donor templates in hepatocytes to treat inherited metabolic diseases of the liver. ASGCT 21st Annual Meeting Abstracts. Molecular Therapy. 2018. 26: 369-370. Chicago, IL (May 2018).
  57. Cottle R, The promise of cell-based gene therapies using non-viral delivery approaches. Proceedings in the International Biomaterials Symposium, Madren Conference Center, Clemson, SC (April 2018).
  58. Bridges PH, Bryson TE, Rathbone T, Cottle RN. CRISPR-Cas9 mediated correction of inherited metabolic disease of the liver. Proceedings of the 3rd Annual Genome Editing & Engineering Conference. San Diego, CA (February 2018).
  59. Rathbone T, Bryson TE, Anglin C, Cottle RN. CRISPR-Cas9 mediated gene modification for correction of familial hypercholesterolemia in mouse hepatocytes. Proceedings of the 2017 Fall Symposium. SC INBRE, Columbia, SC (October 2017).
  60. Bridges PH, Bryson TE, Rathbone T, Cottle RN. Overview of the biomolecular and cellular engineering lab. Proceedings of the 2017 Fall Symposium. SC INBRE, Columbia, SC (October 2017).

  61. Cottle R, Archer D, Bao G. Nuclease mediated genome editing for treating sickle cell disease utilizing non-viral delivery strategies. Proceedings of the 2015 Annual Meeting. BMES, Tampa, FL (October 2015).
  62. Lee C, Lin Y, Preininger M, Cottle R, Cradick TJ, Bao G. Increasing CRISPR specificity for therapeutic applications. Proceedings of the 2014 Annual Meeting. BMES, San Antonio, TX (October 2014).
  63. Cottle R, Archer D, Bao G. Homologous recombination mediated gene repair in K562 cells microinjected with β-globin targeting nucleases using glass microcapillaries. Proceedings from the Pediatric Healthcare Innovation Conference. Emory Children’s Georgia Tech Pediatric Research Alliance, Atlanta, GA (April 2014).
  64. Cottle R, Archer D, Bao G.Genome Editing in CD34+ hematopoietic stem and progenitor cells nucleofected and microinjected with β-globin targeting CRISPR/Cas9. Proceedings from the 2014 Regenerative Medicine Workshop. Parker H. Petit Institute for Bioengineering and Bioscience at the Georgia Institute of Technology, Hilton Head, SC (March 2014).
  65. Cottle R, Sundararaghavan A., Hepler J, Bao G. Protein beacon targeting of inactive heterotrimeric guanine-nucleotide binding protein in live HeLa cells. Proceedings of the 2013 Annual Meeting. BMES, Seattle, WA (September 2013).
  66. Cottle R, David A, Bao D, Bao G. Microinjection-based delivery of beta-globin-targeting TALENs into K562 cells for gene modification. Proceedings of the 2013 Annual Meeting. BMES, Seattle, WA (September 2013).
  67. Cottle R, David A, Bao G. Microinjection-based delivery of β-globin-targeting TALENs into K562 cells for gene modification. Proceedings of the 2013 Pediatric Research Retreat. Emory Children’s Georgia Tech Pediatric Research Alliance, Atlanta, GA (June 2013).
  68. Myers D, Cottle R, Mannino R, Kim H, Bao G, Lam W. Gene correction of rare non-adherent cells using a capture microfluidic and microinjection system. Proceedings of the 2012 Annual Meeting; BMES, Atlanta, GA (October 2012).
  69. Cottle R, Gang B, Archer D, Wilbur L, Myers D. Quantifying the Effects of Nuclease Delivery on the Functionality of Hematopoietic Stem Cells. Proceedings of the 2012 Annual Meeting; BMES, Atlanta, GA (October 2012).
  70. Cottle R., Bao G, Hepler J. Protein beacon targeting of endogenous heterotrimeric guanine-nucleotide binding proteins. Proceedings of the 2012 Annual Meeting; BMES, Atlanta, GA (October 2012).
  71. Sundararaghavan A, Cottle R, Bao G. Quantifying Galpha-I1 subunit protein beacon delivery into live cells permeabilized with streptolysin-o. Proceedings of the 2012 Annual Meeting; BMES, Atlanta, GA (October 2012).

Invited Presentations

  1. Cottle R.. “Advancing cell-based therapy for familial hypercholesterolemia through electroporation-mediated multiplex gene editing and in vivo selection,” Invited speaker, 7th Annual Research Symposium and Retreat, Digestive Disease Research Center, Medical University of South Carolina, Charleston, SC (April 17, 2026).
  2. Cottle R. “Electroporation in Hepatocytes to Evaluate a Cell-Based Gene Editing Strategy for Treating Homozygous Familial Hypercholesterolemia,” Guest speaker, research webinar, Cell & Gene Therapy Review (October 14, 2025).
  3. Cottle R. “Cell therapy combining ex vivo gene editing with hepatocyte transplantation for inherited metabolic liver diseases,” Guest speaker, Miltenyi Mindshare Seminar Series, Miltenyi Biotec (November 22, 2024).
  4. Cottle R. “Cell therapy combining ex vivo gene editing with hepatocyte transplantation for inherited metabolic liver diseases,” Invited speaker, Department of Biomedical Sciences Seminar Series, New York Institute of Technology, College of Osteopathic Medicine, Old Westbury, NY (August 26, 2024).
  5. Cottle R. “Cell-based gene editing therapy for genetic diseases affecting the liver,” Invited speaker, Bioengineering seminar, Joint School of Nanoscience and Nanoengineering, Greensboro, North Carolina (February 16, 2024).
  6. Cottle R. “Liver repopulation by acetaminophen selection of hepatocytes edited ex vivo using nonviral delivery approaches,” Invited speaker, The American Association for the Study of Liver Disease Liver Meeting, Boston, Massachusetts (November 10, 2023).
  7. Cottle R. “Liver repopulation by acetaminophen selection of hepatocytes edited ex vivo using nonviral delivery approaches,” Invited speaker, American Society of Gene and Cell Therapy 26TH Annual Meeting, Los Angeles, California (May 19, 2023).
  8. Cottle R. “A unique journey in academia to advance cell-based gene editing approaches for genetic diseases affecting the liver,” Invited speaker, The 3rd Annual Life Science Women’s Conference, University of South Florida (September 21, 2022).
  9. Cottle R. “Correcting Inherited Metabolic Liver Disease by ex vivo genome editing using nonviral delivery approaches,” Invited speaker, Picture A Scholar at Clemson, Inaugural Women’s Scholar Symposium (March 10, 2022).
  10. Cottle R. “Correcting Inherited Metabolic Liver Disease by ex vivo genome editing using nonviral delivery approaches,” Invited seminar, Biomedical Engineering Seminar, Tufts University, virtual seminar (January 31, 2022)
  11. Cottle R. “Correcting inherited metabolic liver diseases by ex vivo genome editing using nonviral delivery approaches,” Invited seminar, Center for Human Genetics, Clemson University, virtual seminar (September 13, 2021).
  12. Cottle R. “Ex vivo genome editing as a therapeutic approach for genetic diseases”, Invited seminar, Bioengineering Research Seminar, University of Maryland, College Park, MD (February 5, 2021).
  13. Cottle R. “Ex vivo genome editing as a therapeutic approach for genetic diseases”, Invited seminar, Bioengineering Research Seminar, Rochester Institute of Technology, Rochester, NY (March 3, 2020).
  14. Cottle R. “Ex vivo genome editing as a therapeutic approach for inherited metabolic diseases affecting the liver”, Invited seminar, Research Seminar, Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA (January 30, 2020)
  15. Cottle R. “Ex vivo genome editing as a therapeutic approach for genetic diseases”, Invited seminar, Research Seminar, Southern Wesleyan University, Central, SC (January 24, 2020).
  16. Cottle R. “Ex vivo genome editing as a therapeutic approach: Engineering the delivery system and critical challenges”, Invited seminar, Regenerative Medicine & Cell Biology, Digestive Disease Research Center Seminar Series, Medical University of South Carolina, Charleston, SC (April 10, 2019).
  17. Cottle R. “Ex vivo genome editing as a therapeutic approach: Engineering the delivery system and critical challenges”, Invited seminar, Seminar Series, Genetics and Biochemistry, Clemson University, Clemson, SC (March 1, 2019).
  18. Cottle R. “The promise of cell-based gene therapies using non-viral delivery approaches”, Invited seminar, Center for Molecular and Translational Medicine, Seminar Series, Georgia State University, Atlanta, GA (November 21, 2018).
  19. Cottle R, “The promise of cell-based gene therapies using non-viral delivery approaches”, Invited conference speech, 2nd Annual Summit on Stem Cell Research, Cell & Gene Therapy, Atlanta, GA (November 9, 2018).
  20. Cottle R, “Towards ex vivo gene editing in hepatocytes for treatment of inherited liver disease”, Invited conference speech, Genetics Symposium, Clemson, SC (September 27, 2018).
  21. Cottle R, “Novel gene therapy strategy using CRISPR-Cas nucleases and donor template for metabolic liver disease”, Invited conference speech, SC INBRE Science Symposium, Columbia, SC (August 10, 2018).
  22. Cottle R, “The promise of cell-based gene therapies using non-viral delivery approaches”, Invited conference speech, International Biomaterials Symposium, Madren Conference Center, Clemson, SC (April 16, 2018).
  23. Cottle R, “Glass microcapillary mediated microinjection of β-globin targeting TALENs into K562 cells”, Graduate and Postdoc Seminar Series, Georgia Institute of Technology, Atlanta, GA (November 13, 2014).
  24. Cottle R, “Microinjection and nucleofection methods of delivering β-globin targeting TALENs into K562 cells”, Nanomedicine Development Center for Nucleoprotein Machines Internal Review Meeting, Atlanta, GA (October 7, 2014).
  25. Cottle R, “Quantifying the effects of nuclease delivery and gene correction on the functionality of hematopoietic stem cells”, Molecular Biophysics Seminar Series, Georgia Institute of Technology, Atlanta, GA (February 6, 2012).

Patents

  1. “Inline Intravenous Fluid Sterilizer”, USA, US 8747764 B1, with SD Reinitz, KE Boucher, and CA Burchman.